心血管病理生理学和治疗中的BRD蛋白的进展:一篇综述
Yujie Jiang1, Jingting Jiang1, Sunye Feng1
1School of Pharmacy, Nanjing University of Chinese Medicine, Nanjing, 210023, China.
International journal of biological macromolecules
|November 7, 2025
概括
含基蛋白蛋白 (BRD) 是心血管疾病 (CVD) 中的关键表观遗传调节者. 准BRD为心血管疾病提供了新的治疗策略,影响血管炎症,功能障碍和纤维化.
科学领域:
- 心血管表观遗传学 心血管表观遗传学
- 分子生物学分子生物学
- 生物化学 生物化学
背景情况:
- 表观遗传调节在心血管疾病 (CVD) 发病过程中至关重要.
- 基体 (BRDs) 是蛋白质模块,可以识别乙化组织蛋白,作为表观遗传阅读器.
- BRDs将基因素乙化与心血管细胞的基因表达变化联系起来.
研究的目的:
- 审查BRD蛋白在心血管疾病发病过程中的多方面的作用.
- 阐明BRD对心血管疾病影响的机制.
- 突出针对心血管疾病治疗的BRD的临床应用.
主要方法:
- 在心血管生物学中对BRD研究的文献综述.
- 对血管炎症,内皮功能障碍,VSMC调节,心肌细胞亡和纤维化中的BRD功能进行分析.
- 探索针对BRD的治疗策略.
主要成果:
- BRDs在心血管疾病中协调关键的病理过程.
- BRD 蛋白质显著影响各种心血管疾病.
- 准BRD为新型心血管疾病治疗提供了潜力.
结论:
- BRD蛋白质是心血管健康和疾病中基因表达的关键调节者.
- 了解BRD机制可以了解心血管疾病的进展.
- 针对BRD提供了对心血管疾病诊断和治疗的有希望的途径.
相关概念视频
Coronary Artery Disease I: Introduction
863
Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
863
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
902
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
902
Coronary Artery Disease II: Pathophysiology
355
Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
355
Heart Failure Drugs: β-Blockers
747
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
747
Atherosclerosis III: Management
307
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
307
Peripheral Artery Disease III: Interprofessional Care
231
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
231


